NO20050867L - Benzensulfonat av 4-fluor-2-cyano-pyrrolidinderivater - Google Patents
Benzensulfonat av 4-fluor-2-cyano-pyrrolidinderivaterInfo
- Publication number
- NO20050867L NO20050867L NO20050867A NO20050867A NO20050867L NO 20050867 L NO20050867 L NO 20050867L NO 20050867 A NO20050867 A NO 20050867A NO 20050867 A NO20050867 A NO 20050867A NO 20050867 L NO20050867 L NO 20050867L
- Authority
- NO
- Norway
- Prior art keywords
- fluoro
- cyano
- benzenesulfonate
- pyrrolidine derivatives
- stability
- Prior art date
Links
- HHFUFGKACHWIAV-UHFFFAOYSA-N 4-fluoropyrrolidine-2-carbonitrile Chemical class FC1CNC(C#N)C1 HHFUFGKACHWIAV-UHFFFAOYSA-N 0.000 title 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 title 1
- 229940077388 benzenesulfonate Drugs 0.000 title 1
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 abstract 1
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyrrole Compounds (AREA)
Abstract
(2S,4S)-2-cyano-4-fiuor-l-[(2-hydroksy-l,l-dimetyl)etylamino]acetylpyrrohdinbenzensulfonatsom viser en utmerket DPPIV-inhiberende aktivitet og har egenskaper som er nødvendige som en medisin, for eksempel en høy stabilitet. Denne forbindelse kan lett oppnås i form av svært stabile krystaller som har en homogen form og har en høy stabilitet i fast form.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002249821 | 2002-08-29 | ||
PCT/JP2003/010828 WO2004020407A1 (ja) | 2002-08-29 | 2003-08-27 | 4−フルオロ−2−シアノピロリジン誘導体ベンゼンスルホン酸塩 |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20050867L true NO20050867L (no) | 2005-02-18 |
Family
ID=31972599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20050867A NO20050867L (no) | 2002-08-29 | 2005-02-18 | Benzensulfonat av 4-fluor-2-cyano-pyrrolidinderivater |
Country Status (19)
Country | Link |
---|---|
US (1) | US7304166B2 (no) |
EP (1) | EP1535907A4 (no) |
JP (1) | JP3746063B2 (no) |
KR (1) | KR100582141B1 (no) |
CN (1) | CN1310885C (no) |
AU (1) | AU2003261748B2 (no) |
BR (1) | BR0313831A (no) |
CA (1) | CA2496623C (no) |
EA (1) | EA007613B1 (no) |
EC (1) | ECSP055708A (no) |
HK (1) | HK1082497A1 (no) |
HR (1) | HRP20050205A2 (no) |
MX (1) | MXPA05002253A (no) |
NO (1) | NO20050867L (no) |
NZ (1) | NZ538956A (no) |
PL (1) | PL374664A1 (no) |
UA (1) | UA78104C2 (no) |
WO (1) | WO2004020407A1 (no) |
ZA (1) | ZA200501418B (no) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
EP1852419A4 (en) | 2005-01-27 | 2009-03-04 | Mitsui Chemicals Inc | PROCESS FOR PREPARING A FLUORINATED PROLIN DERIVATIVE |
JP2008024592A (ja) * | 2005-01-28 | 2008-02-07 | Taisho Pharmaceut Co Ltd | シアノピロリジン誘導体含有固形製剤用組成物、それを含有する固形製剤及びその製造方法 |
WO2006100181A2 (en) | 2005-03-22 | 2006-09-28 | F. Hoffmann-La Roche Ag | New salt and polymorphs of a dpp-iv inhibitor |
PT1942898E (pt) | 2005-09-14 | 2011-12-20 | Takeda Pharmaceutical | Inibidores da dipeptidilpeptidase para o tratamento da diabetes |
JP5122462B2 (ja) | 2005-09-16 | 2013-01-16 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼ阻害剤 |
WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
CN101652147B (zh) | 2007-04-03 | 2013-07-24 | 田边三菱制药株式会社 | 二肽基肽酶iv抑制化合物和甜味剂的并用 |
CL2008003653A1 (es) * | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
EP2108960A1 (en) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY |
AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
MX2012011631A (es) | 2010-04-06 | 2013-01-18 | Arena Pharm Inc | Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con el mismo. |
US10894787B2 (en) | 2010-09-22 | 2021-01-19 | Arena Pharmaceuticals, Inc. | Modulators of the GPR119 receptor and the treatment of disorders related thereto |
US20140018371A1 (en) | 2011-04-01 | 2014-01-16 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
US20140066369A1 (en) | 2011-04-19 | 2014-03-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
US20140038889A1 (en) | 2011-04-22 | 2014-02-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
CN107683135A (zh) | 2015-03-09 | 2018-02-09 | 因特克林医疗有限公司 | 用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法 |
SG11201909046XA (en) | 2017-04-03 | 2019-10-30 | Coherus Biosciences Inc | PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4432987A (en) | 1982-04-23 | 1984-02-21 | Pfizer Inc. | Crystalline benzenesulfonate salts of sultamicillin |
GB8608335D0 (en) | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
TW492957B (en) * | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
US6011155A (en) * | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
JP3107784B2 (ja) | 1996-12-26 | 2000-11-13 | 宇部興産株式会社 | 光学活性ピペリジン誘導体の酸付加塩及びその製法 |
TW486475B (en) | 1996-12-26 | 2002-05-11 | Ube Industries | Acid addition salt of optically active piperidine compound and process for preparing the same |
US6252063B1 (en) | 1998-12-01 | 2001-06-26 | Merck & Co., Inc. | Crystalline salts of a carbapenem antibiotic |
TWI243162B (en) * | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
-
2003
- 2003-08-27 CA CA002496623A patent/CA2496623C/en not_active Expired - Fee Related
- 2003-08-27 BR BR0313831-3A patent/BR0313831A/pt not_active IP Right Cessation
- 2003-08-27 ZA ZA200501418A patent/ZA200501418B/xx unknown
- 2003-08-27 CN CNB038203367A patent/CN1310885C/zh not_active Expired - Fee Related
- 2003-08-27 EP EP03791325A patent/EP1535907A4/en not_active Withdrawn
- 2003-08-27 UA UAA200502704A patent/UA78104C2/uk unknown
- 2003-08-27 JP JP2004532725A patent/JP3746063B2/ja not_active Expired - Fee Related
- 2003-08-27 KR KR1020057003211A patent/KR100582141B1/ko not_active IP Right Cessation
- 2003-08-27 PL PL03374664A patent/PL374664A1/xx not_active Application Discontinuation
- 2003-08-27 EA EA200500420A patent/EA007613B1/ru not_active IP Right Cessation
- 2003-08-27 AU AU2003261748A patent/AU2003261748B2/en not_active Ceased
- 2003-08-27 MX MXPA05002253A patent/MXPA05002253A/es active IP Right Grant
- 2003-08-27 WO PCT/JP2003/010828 patent/WO2004020407A1/ja not_active Application Discontinuation
- 2003-08-27 NZ NZ538956A patent/NZ538956A/en unknown
- 2003-08-27 US US10/525,748 patent/US7304166B2/en not_active Expired - Fee Related
-
2005
- 2005-02-18 NO NO20050867A patent/NO20050867L/no not_active Application Discontinuation
- 2005-03-03 HR HR20050205A patent/HRP20050205A2/hr not_active Application Discontinuation
- 2005-03-28 EC EC2005005708A patent/ECSP055708A/es unknown
-
2006
- 2006-02-24 HK HK06102523A patent/HK1082497A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP1535907A1 (en) | 2005-06-01 |
EA200500420A1 (ru) | 2005-08-25 |
ECSP055708A (es) | 2005-08-11 |
AU2003261748B2 (en) | 2006-11-23 |
JP3746063B2 (ja) | 2006-02-15 |
CN1678575A (zh) | 2005-10-05 |
PL374664A1 (en) | 2005-10-31 |
WO2004020407A1 (ja) | 2004-03-11 |
AU2003261748A1 (en) | 2004-03-19 |
KR20050059094A (ko) | 2005-06-17 |
US7304166B2 (en) | 2007-12-04 |
NZ538956A (en) | 2006-08-31 |
US20060106087A1 (en) | 2006-05-18 |
CA2496623C (en) | 2008-02-12 |
HRP20050205A2 (en) | 2005-10-31 |
UA78104C2 (en) | 2007-02-15 |
EP1535907A4 (en) | 2006-11-29 |
HK1082497A1 (en) | 2006-06-09 |
ZA200501418B (en) | 2006-10-25 |
JPWO2004020407A1 (ja) | 2005-12-15 |
EA007613B1 (ru) | 2006-12-29 |
CN1310885C (zh) | 2007-04-18 |
CA2496623A1 (en) | 2004-03-11 |
KR100582141B1 (ko) | 2006-05-22 |
BR0313831A (pt) | 2005-07-05 |
MXPA05002253A (es) | 2005-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20050867L (no) | Benzensulfonat av 4-fluor-2-cyano-pyrrolidinderivater | |
NO20071078L (no) | Antivirale forbindelser | |
NO20070866L (no) | Antivirale forbindelser. | |
SV2008002542A (es) | Formas solidas cristalinas de tigeciclina y metodos para preparar los mismos ref. 01142.0379-00267 (am101946sv) | |
MX2007005933A (es) | Compuestos de acetamida como fungicidas. | |
CR8402A (es) | Indazol-o-glucosidos sustitutos | |
NO20054787L (no) | Indenderivater som farmasotiske midler | |
CL2004000849A1 (es) | Compuestos derivados de benzamidas-2-hidroxi-3-diaminoalcanos, utiles para el tratamiento o la prevencion de alzheimer, sindrome de down, hemorragia cerebral hereditaria, demencias degenerativas y otras. | |
NO20080622L (no) | Disykloalkylurea-glukokinase aktivatorer | |
EA200601554A1 (ru) | Замещенные индол-о-глюкозиды | |
NO20071549L (no) | Nye benzofuserte heteroalrylsulfamidderivater, anvendelige som anti-krampemidler | |
CY1110225T1 (el) | Κυκλικοι αναστολεις πρωτεϊνικης τυροσινικης κινασης | |
DE602004016563D1 (de) | Nukleierungsmittel | |
NO20075616L (no) | Tripeptider som hepatitt C virus inhibitorer | |
ATE377060T1 (de) | Pha-klebstoffe | |
DE60334536D1 (de) | Furylverbindungen | |
CY1113314T1 (el) | (3-αρυλ-πιπεραζιν-1-υλ) παραγωγα της 6,7-διαλκοξυκιναζολινης, 6,7-διαλκοξυφθαλαζινης και 6,7-διαλκοξυϊσοκινολινης | |
NO20055612L (no) | Anti-inflammatoriske fosfonatforbindelser | |
TW200720409A (en) | High clarity cholesteric liquid crystal films | |
NO20083325L (no) | Karbonater av antibiotiske fenicolforbindelser | |
DK1519944T3 (da) | Fremgangsmåder til fremstilling af fibrinogen | |
EP1188769A3 (en) | High resolution crystal structure of the ribosome and design of protein synthesis inhibitors | |
WO2006097617A3 (fr) | Nouveaux derives dihydropyrimidines et leur utilisation comme agents anti-cancereux | |
MXPA05002489A (es) | Composiciones para el cuidado personal basadas en alcohol ramificado. | |
NO20043842L (no) | Nye krystallformer av atorvastatinhemikalsium og fremgangsmater for fremstilling derav, savel som nye fremgangsmater for fremstilling av atorvastatinhemikalsiumform I, VIII og IX |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |